盧修斯 吉瑞替尼 Gilteritinib 線上購買
吉瑞替尼是一種於2018年11月在美國核准上市的處方藥，標靶FMS樣酪胺酸激酶3（FLT3）及其突變（包括FLT3-ITD及FLT3-TKD如D835Y、I836等），使用時需謹遵醫囑。
查看商品
ADMIRAL 和 COMMODORE 試驗的事後分析：吉瑞替尼單藥治療復發/難治性 FLT3 突變型 AML 的起效時間 – aml-hub.com
Post hoc analysis of the ADMIRAL and COMMODORE trials: Timing of response with gilteritinib mono…
正文內容
During the 66th ASH Annual Meeting and Exposition, Wang presented findings from a post hoc analysis of the ADMIRAL and COMMODORE trials investigating the timing of response to gilteritinib in patients with R/R FLT3m AML.
文章相關商品
系統已根據文章標題、摘要和正文，自動匹配目前在售的強相關藥品。
吉瑞替尼片 GILLIDX Gilteritinib 40mg
吉列替尼是一種有效、選擇性、口服FMS樣酪胺酸激酶3（FLT3）抑制劑。吉瑞替尼的核准是基於一項全球多中心開放性隨機對照的III期臨床試驗ADMIRAL研究，該研究最終納入371例血液或骨髓檢測到FLT3突變的複發或難治性AML患者，並以2:1比例隨機分配，分別接受吉瑞替尼或挽救性化療。 ADMIRAL研究的主要複合終點為總存活期（OS）和伴隨完全或部分血液學恢復的完全緩解（CR/CRh）率。這項研究結果發表在權威醫學期刊《新英格蘭醫學雜誌》（NEJM）。
查看商品
常見問題
Which products are related to this article?
The system matched these relevant products from the article content: 盧修斯 吉瑞替尼 Gilteritinib 線上購買、吉瑞替尼片 GILLIDX Gilteritinib 40mg.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.
